Genomtec SA (GMT) Stock Statistics & Valuation Metrics

Genomtec SA has a market cap or net worth of zł63.31M. The enterprise value is zł76.31M.

Genomtec SA has 17,064,634 shares outstanding. The number of shares has decreased by -2.65% in one year.

Genomtec SA’s return on equity (ROE) is -1.13 and return on invested capital (ROIC) is -115.06%.

The current PE Ratio of Genomtec SA is ―. Genomtec SA’s PEG ratio is 0.31.

In the last 12 months, Genomtec SA had revenue of 21.00K and earned -10.43M in profits. Earnings per share was -0.69.

In the last 12 months, operating cash flow was -9.73M and capital expenditures -119.00K, giving a free cash flow of -9.85M billion.

Genomtec SA pays an annual dividend of ―, resulting in a dividend yield of ―

Genomtec SA upcoming earnings date is Oct 5, 2026, TBA (Confirmed).

Genomtec SA as a current ratio of 2.26, with Debt / Equity ratio of 25.36%

In the past 12 months, Genomtec SA has paid -33.00K in taxes.

Genomtec SA EV to EBITDA ratio is -4.54, with an EV/FCF ratio of -4.74.

Genomtec SA has zł2.60M in cash and marketable securities with zł1.78M in debt, giving a net cash position of zł825.00K billion.

Gross margin is -31709.38%, with operating margin of -70371.43%, and net profit margin of -49671.43%.

The average price target for Genomtec SA is ―, which is 11.43% higher than the current price. The consensus rating is ―